Article
Medicine, General & Internal
Mihir M. Desai, Giovanni E. Cacciamani, Karanvir Gill, Juanjuan Zhang, Lihua Liu, Andre Abreu, Inderbir S. Gill
Summary: Analysis of the recent SEER data reveals a significant increase in the incidence rates of mPCa, which coincides with the USPSTF recommendations against PCa screening. These trends are observed across different races and age groups and are associated with changes in screening practices.
Article
Biochemistry & Molecular Biology
Linda Kachuri, Thomas J. Hoffmann, Yu Jiang, Sonja I. Berndt, John P. Shelley, Kerry R. Schaffer, Mitchell J. Machiela, Neal D. Freedman, Wen-Yi Huang, Shengchao A. Li, Ryder Easterlin, Phyllis J. Goodman, Cathee Till, Ian Thompson, Hans Lilja, Stephen K. Van Den Eeden, Stephen J. Chanock, Christopher A. Haiman, David V. Conti, Robert J. Klein, Jonathan D. Mosley, Rebecca E. Graff, John S. Witte
Summary: Prostate-specific antigen (PSA) screening for prostate cancer remains controversial due to overdiagnosis and overtreatment. However, accounting for genetic determinants of PSA variation may improve screening accuracy.
Article
Oncology
Naseruddin Hoti, Tung-Shing Lih, Mingming Dong, Zhen Zhang, Leslie Mangold, Alan W. Partin, Lori J. Sokoll, Qing Kay Li, Hui Zhang
Summary: Prostate cancer is a leading cause of death in men in the United States. The commonly used method of diagnosis involves digital rectal examination and serum PSA assay, followed by prostate gland biopsy. However, false elevations in PSA levels can lead to unnecessary biopsies. This study evaluated the use of urinary PSA as a predictive marker for aggressive prostate cancer, and found that it had higher predictive power compared to serum PSA. Combining serum and urinary PSA levels further enhanced the detection of aggressive prostate cancer.
Article
Oncology
Thanya Pathirana, Rehan Sequeira, Chris Del Mar, James A. Dickinson, Bruce K. Armstrong, Katy J. L. Bell, Paul Glasziou
Summary: The relationship between PSA testing rates and prostate cancer incidence is evident. Deviations from this pattern may be explained by less utilization of TURP in BPH management and subsequent incidental cancer detection in TURP tissue specimens. Prostate cancer mortality initially rose and then decreased, possibly due to an initial tendency to over-attribute deaths of uncertain cause in older men with a prostate cancer diagnosis. The decrease in mortality rates was much smaller than the increase in incidence, suggesting substantial overdiagnosis of prostate cancer after the introduction of PSA testing.
CANCER EPIDEMIOLOGY
(2022)
Review
Materials Science, Multidisciplinary
Baljit Singh, Shiliang Ma, Tony O. O. Hara, Sargun Singh
Summary: Cancer, specifically prostate cancer, remains a significant challenge despite advances in detection methods, therapeutic agents, and biomarkers. This article reviews recent achievements in utilizing nanomaterials and nanotechnology for the development of biosensors targeting various biomarkers, including prostate-specific antigen (PSA), sarcosine oxidase, prostate cancer antigen 3 (PCA3), vascular endothelial growth factor (VEGF), and prostate-specific membrane antigen (PSMA). The integration of nanotechnology and different biomarkers is providing insights into the development of biosensors for prostate cancer diagnostics.
ADVANCED MATERIALS TECHNOLOGIES
(2023)
Article
Medicine, General & Internal
Jonas Hugosson, Marianne Mansson, Jonas Wallstrom, Ulrika Axcrona, Sigrid V. Carlsson, Lars Egevad, Kjell Geterud, Ali Khatami, Kimia Kohestani, Carl-Gustaf Pihl, Andreas Socratous, Johan Stranne, Rebecka Arnsrud Godtman, Mikael Hellstrom
Summary: MRI-directed targeted biopsy for prostate cancer screening reduces the risk of overdiagnosis by half compared to systematic biopsy, but may delay the detection of intermediate-risk tumors in a small proportion of patients.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Irene Oi Ling Wong, Yan Ting Lam, Kwok Fai Lam, Benjamin John Cowling, Gabriel Matthew Leung
Summary: Hong Kong has an ageing Chinese population with high life expectancy and a rising number of cancer cases. The increasing trend in cancer diagnoses in Hong Kong over the past decades is mainly attributed to population growth and ageing, with changes in disease risk inhibiting this trend.
Article
Oncology
Wen-Qiang He, Chenxi Li
Summary: This study revealed wide variations in cervical cancer incidence and mortality globally, with East Africa having the highest rates. Factors such as human papillomavirus, human immunodeficiency virus infection, and cervical cancer screening coverage were associated with the incidence and mortality of cervical cancer. While most countries have shown reduction in cervical cancer incidence and mortality, there is an increasing trend among younger women in some developed countries, emphasizing the importance of effective cancer screening.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Biophysics
Ana Diaz-Fernandez, Rebeca Miranda-Castro, Noemi de-los-Santos-Alvarez, Maria Jesus Lobo-Castanon, Pedro Estrela
Summary: The study presents an improved impedimetric aptamer-based sensor for dual recognition of PSA with two different aptamers, showing a dynamic range in serum between 0.26 and 62.5 ng/mL with good reproducibility. The platform could be used as a minimally invasive method for the diagnosis of prostate cancer, as it demonstrates excellent correlation between glycan score and the known diagnosis of patients with different pathologies.
BIOSENSORS & BIOELECTRONICS
(2021)
Article
Oncology
Kevin H. Kensler, Claire H. Pernar, Brandon A. Mahal, Paul L. Nguyen, Quoc-Dien Trinh, Adam S. Kibel, Timothy R. Rebbeck
Summary: The frequency of prostate cancer screening varies by race and ethnicity, with a steeper decline in PSA testing among younger non-Hispanic Black men relative to non-Hispanic White men since 2012. The incidence rate ratio for localized prostate cancer modestly increased for non-Hispanic Black men compared to non-Hispanic White men after 2012.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2021)
Letter
Medicine, General & Internal
Haluk Damgacioglu, Todd Burus, Kalyani Sonawane, Elizabeth Hill, Krystle A. Lang Kuhs, Ashish A. Deshmukh
Summary: This study examines the recent trends in rates of cervical cancer incidence and incidence-based mortality among women in Appalachian and non-Appalachian Kentucky counties.
Article
Oncology
Gholamreza Roshandel, Jacques Ferlay, Ali Ghanbari-Motlagh, Elham Partovipour, Fereshteh Salavati, Kimia Aryan, Gohar Mohammadi, Mostafa Khoshaabi, Alireza Sadjadi, Masoud Davanlou, Fereshteh Asgari, Hakimeh Abadi, Abbas Aghaei, Seyed-Vahid Ahmadi-Tabatabaei, Kazem Alizadeh-Barzian, Abbasali Asgari, Noorali Asgari, Soheyla Azami, Maria Cheraghi, Floria Enferadi, Masoumeh Eslami-Nasab, Jila Fakhery, Mohsen Farahani, Solmaz Farrokhzad, Mansooreh Fateh, Ali Ghasemi, Fatemeh Ghasemi-Kebria, Hajar Gholami, Arash Golpazir, Susan Hasanpour-Heidari, Narjes Hazar, Hosein Hoseini-Hoshyar, Mohsen Izadi, Mahdi Jahantigh, Ahmad Jalilvand, Seyed-Mehrdad Jazayeri, Yasan Kazemzadeh, Maryam Khajavi, Maryam Khalednejad, Marziyeh Khanloghi, Maryam Kooshki, Amineh Madani, Mahdi Mirheidari, Hosein Mohammadifar, Zeinab Moinfar, Yasaman Mojtahedzadeh, Ali Morsali, Rita Motidost-Komleh, Tahereh Mousavi, Maboobeh Narooei, Mohammad Nasiri, Sharareh Niksiar, Mehdi Pabaghi, Habibollah Pirnejad, Azadeh Pournajaf, Gita Pourshahi, Amir Rahnama, Bahman Rashidpoor, Zahra Ravankhah, Khadijeh Rezaei, Abbas Rezaianzadeh, Gholamreza Sadeghi, Mohammad Salehifar, Athareh Shahdadi, Mehraban Shahi, Farrokh Sharifi-Moghaddam, Roya Sherafati, Ali Soleimani, Maryam Soltany-hojatabad, Mohammad-Hossein Somi, Sohrab Yadolahi, Majid Yaghoubi-Ashrafi, Aliakbar Zareiyan, Hossein Poustchi, Kazem Zendehdel, Afshin Ostovar, Ghasem Janbabaei, Alireza Raeisi, Elisabete Weiderpass, Reza Malekzadeh, Freddie Bray
Summary: The study predicts an increase in the number of cancer patients in Iran by 2025, with changes in risk and population structure contributing to this rise. Breast, colorectal, and stomach cancers are the most common types in Iran and are expected to remain the leading cancers nationally in 2025.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Review
Endocrinology & Metabolism
Leonardo Rossi, Gabriele Materazzi, Sohail Bakkar, Paolo Miccoli
Summary: Thyroid cancer incidence has rapidly increased over the past decade, making thyroid surgery one of the most common procedures. Alternative surgical techniques have been developed to provide better cosmetic results, with some gaining popularity and favor among the scientific community.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Public, Environmental & Occupational Health
Le Wang, Bin Lu, Mengjie He, Youqing Wang, Zongping Wang, Lingbin Du
Summary: The study evaluated the current global status of prostate cancer incidence and mortality. The findings indicate that the increase in prostate cancer incidence and the decrease in mortality have slowed down in recent years.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Oncology
Cara Reiter-Brennan, Omar Dzaye, Mouaz H. Al-Mallah, Zeina Dardari, Clinton A. Brawner, Lois E. Lamerato, Steven J. Keteyian, Jonathan K. Ehrman, Michael J. Blaha, Kala Visvanathan, Catherine H. Marshall
Summary: The study found that men with high fitness are more likely to undergo PSA screening and have a higher incidence of prostate cancer. However, men with high fitness have a lower risk of death after a prostate cancer diagnosis.
Article
Oncology
Boshen Jiao, Roman Gulati, Hormuzd A. Katki, Philip E. Castle, Ruth Etzioni
Summary: The effectiveness of multi-cancer testing depends on specificity and sensitivity, with higher prevalence and mortality cancers being more favorable in reducing unnecessary confirmation tests. The benefits and risks of the test depend on the characteristics of the diseases and the effectiveness of treatments.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2022)
Editorial Material
Oncology
Ruth Etzioni, Roman Gulati, Noel S. Weiss
Summary: This article discusses the potential impact of multicancer early detection tests and highlights three key factors that influence the balance of benefits and harms in early detection testing, namely the ability to confirm cancer signals, population testing strategies, and the natural history of targeted cancers. It emphasizes the critical gaps in current knowledge that hinder accurate predictions of the clinical impact of MCED testing.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2022)
Article
Urology & Nephrology
Kara N. Maxwell, Heather H. Cheng, Jacquelyn Powers, Roman Gulati, Elisa M. Ledet, Casey Morrison, Anh Le, Ryan Hausler, Jill Stopfer, Sophie Hyman, Wendy Kohlmann, Anne Naumer, Jennie Vagher, Samantha E. Greenberg, Lorraine Naylor, Mercy Laurino, Eric Q. Konnick, Brian H. Shirts, Saud H. AlDubayan, Eliezer M. Van Allen, Bastien Nguyen, Joseph Vijai, Wassim Abida, Maria Carlo, Marianne Dubard-Gault, Daniel J. Lee, Luke D. Maese, Diana Mandelker, Bruce Montgomery, Michael J. Morris, Piper Nicolosi, Robert L. Nussbaum, Lauren E. Schwartz, Zsofia Stadler, Judy E. Garber, Kenneth Offit, Joshua D. Schiffman, Peter S. Nelson, Oliver Sartor, Michael F. Walsh, Colin C. Pritchard
Summary: Complementary analysis of prostate cancer incidence in LFS males and gTP53 prevalence in prostate cancer cohorts suggests that gTP53 predisposes to aggressive prostate cancer. Prostate cancer should be considered as part of LFS screening protocols and TP53 should be considered in germline prostate cancer susceptibility testing.
Article
Urology & Nephrology
Sarah P. Psutka, Roman Gulati, Michael A. S. Jewett, Kamel Fadaak, Antonio Finelli, Laura Legere, Todd M. Morgan, Phillip M. Pierorazio, Mohamad E. Allaf, Jeph Herrin, Christine M. Lohse, R. Houston Thompson, Stephen A. Boorjian, Thomas D. Atwell, Grant D. Schmit, Brian A. Costello, Nilay D. Shah, Bradley C. Leibovich
Summary: This study aimed to develop prediction models for personalized treatment of clinical T1 renal cortical masses, considering risks of cancer-specific mortality, other-cause mortality, and complications. The models can provide risk assessment for patients undergoing different treatments, aiding in shared decision-making and treatment selection.
Meeting Abstract
Oncology
Michael Thomas Schweizer, Roman Gulati, Yang Liu, Alexander K. Hakansson, Elai Davicioni, Lawrence True, William J. Ellis, George Schade, Robert B. Montgomery, Sonia Wadhera, Katie Nega, Kenneth J. Pienta, Peter Nelson, Jonathan L. Wright, Daniel W. Lin
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Alexandra Sokolova, Roman Gulati, Heather H. Cheng, Tomasz M. Beer, Julie N. Graff, Melanie Amador, Andrea Toulouse, Kamilah Taylor, Shawna Bailey, Steven Smith, Shaadi Tabatabaei, Ryan Sinit, Rachel Slottke, Jacqueline Vuky, Todd Yezefski, Petros Grivas, Evan Y. Yu, Michael Thomas Schweizer
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Lukas Owens, Roman Gulati, Ruth Etzioni
Summary: Predicting the impact of cancer screening on disease-specific mortality based on stage shift alone is unreliable, as survival distributions vary across different cancer types. Stage shift does not consistently predict mortality reduction in cancers potentially detectable by MCED tests.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2022)
Article
Pathology
Hasim Bakbak, Erolcan Sayar, Harsimar B. Kaur, Daniela C. Salles, Radhika A. Patel, Jessica Hicks, Tamara L. Lotan, Angelo M. De Marzo, Roman Gulati, Jonathan I. Epstein, Michael C. Haffner
Summary: Genomic studies have shown that prostate cancer exhibits a high level of heterogeneity. Adjacent Gleason pattern 3 and pattern 5 lesions are found to be clonally related, although they may have divergent genetic and morphologic evolution. This study also reveals a lower-than-expected rate of PTEN loss in Gleason score 3+5=8 or 5+3=8 tumors.
Article
Urology & Nephrology
Michael T. Schweizer, Lawrence True, Roman Gulati, Yibai Zhao, William Ellis, George Schade, Bruce Montgomery, Sonia Goyal, Katie Nega, Alexander K. Hakansson, Yang Liu, Elai Davicioni, Kenneth Pienta, Peter S. Nelson, Daniel Lin, Jonathan Wright
Summary: Apalutamide can decrease the rate of active surveillance attrition in men with lower-risk prostate cancer by downstaging low-grade tumors.
JOURNAL OF UROLOGY
(2023)
Article
Oncology
Michael T. Schweizer, Roman Gulati, Todd Yezefski, Heather H. Cheng, Elahe Mostaghel, Michael C. Haffner, Radhika A. Patel, Navonil De Sarkar, Gavin Ha, Ruth Dumpit, Brianna Woo, Aaron Lin, Patrick Panlasigui, Nerina McDonald, Michael Lai, Katie Nega, Jeannette Hammond, Petros Grivas, Andrew Hsieh, Bruce Montgomery, Peter S. Nelson, Evan Y. Yu
Summary: This study investigated the use of Bipolar androgen therapy (BAT) in metastatic castration-resistant prostate cancer (mCRPC) and found that BAT plus olaparib combination therapy can achieve high response rates and long progression-free survival. The clinical effects of this treatment may be related to DNA damage induction and synergy with PARP inhibitors. The presence or absence of HRR gene mutations does not affect the efficacy.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Editorial Material
Oncology
Lukas Owens, Kemal Caglar Gogebakan, Usha Menon, Roman Gulati, Noel S. Weiss, Ruth Etzioni
Summary: Multicancer early detection tests are prompting a reconsideration of short-term endpoints for cancer screening trials. Stage-shift models that preserve prognostic subtype might predict different mortality reductions compared to models that ignore subtype. We examine the implications of preserving prognostic subtypes in ovarian and prostate cancers and its impact on short-term endpoints based on stage in cancer screening trials.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2023)
Article
Medicine, Research & Experimental
Erolcan Sayar, Radhika A. Patel, Ilsa M. Coleman, Martine P. Roudier, Ailin Zhang, Pallabi Mustafi, Jin-Yih Low, Brian Hanratty, Lisa S. Ang, Vipul Bhatia, Mohamed Adil, Hasim Bakbak, David A. Quigley, Michael T. Schweizer, Jessica E. Hawley, Lori Kollath, Lawrence D. True, Felix Y. Feng, Neil H. Bander, Eva Corey, John K. Lee, Colm Morrissey, Roman Gulati, Peter S. Nelson, Michael C. Haffner
Summary: Prostate-specific membrane antigen (PSMA) expression is heterogeneous in metastatic castration-resistant prostate cancer (mCRPC), with some cases showing no detectable PSMA and others showing heterogeneous expression across metastases. Loss of PSMA is associated with epigenetic changes, including CpG methylation and loss of H3K27 acetylation at the FOLH1 locus. Treatment with HDAC inhibitors can reverse this repression and restore PSMA expression. These findings provide insights into PSMA expression patterns and regulation in mCRPC, and suggest a potential therapeutic strategy using epigenetic therapies to augment PSMA levels.
Meeting Abstract
Oncology
Ruth Etzioni, Roman Gulati, Lukas Owens, Jane Lange, Marc D. Ryser
CANCER PREVENTION RESEARCH
(2023)
Meeting Abstract
Urology & Nephrology
Spyridon Basourakos, Roman Gulati, Randy Vince, Daniel Spratt, Patrick Lewicki, Alexander Hill, Yaw Nyame, Jennifer Cullen, Sarah Markt, Christopher Barbieri, Jim Hu, Jonathan Shoag
JOURNAL OF UROLOGY
(2022)
Article
Health Care Sciences & Services
Eveline A. M. Heijnsdijk, Roman Gulati, Jane M. Lange, Alex Tsodikov, Robin Roberts, Ruth Etzioni
Summary: This study evaluated the expected population outcomes and resource use of conservative prostate-specific antigen screening programs in the Bahamas, finding that limited screening programs offer modest benefits that vary with screening ages and frequency.